| Autor: |
Riggers DS; Department for Small Animals, College of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany., Xenoulis PG; Clinic of Medicine, Faculty of Veterinary Science, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece., Karra DA; Clinic of Medicine, Faculty of Veterinary Science, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece., Enderle LL; Department for Small Animals, College of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany., Köller G; Department for Large Animals, College of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany., Böttcher D; Institute of Veterinary Pathology, College of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany., Steiner JM; Gastrointestinal Laboratory, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843-4474, USA., Heilmann RM; Department for Small Animals, College of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany. |
| Abstrakt: |
Diagnosis of feline chronic inflammatory enteropathies (CIE) and the differentiation from small cell intestinal lymphoma (SCL) can be challenging. Intestinally expressed calprotectin (S100A8/A9 protein complex) appears to be part of the complex pathogenesis of feline chronic enteropathies (FCE). Fecal calprotectin is a non-invasive biomarker for intestinal inflammation in humans and dogs but has not yet been evaluated in cats. We hypothesized that fecal calprotectin (fCal) concentrations are increased in FCE, correlate with clinical and/or histologic disease severity, and distinguish cases of CIE from SCL. This case-control study included fecal samples and patient data from cats with CIE ( n = 34), SCL ( n = 17), other gastrointestinal (GI) diseases ( n = 16), and cats with no clinical signs of GI disease ( n = 32). fCal concentrations were measured using the immunoturbidimetric fCal turbo assay (Bühlmann Laboratories). Compared to healthy cats, fCal concentrations were significantly increased in CIE, SCL, and other diseases (all p < 0.0001), but were not different between these three groups (all p > 0.05), or between cats with extra-GI diseases and healthy controls. These findings suggest that fCal may have utility as a clinical biomarker for FCE but not for intestinal disease differentiation. It further supports the role of calprotectin in the pathogenesis of the spectrum of FCE, which includes CIE and SCL. |
